Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.69 |
| ▸ | HTR1A | P08908 | 10/20 | 0.57 |
| ▸ | HTR2A | P28223 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11076838 | 1.00 | KDM4E (0.69) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL6898974 | 0.87 | KDM4E (0.70) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL6901789 | 0.87 | KDM4E (0.74) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL27079807 | 0.81 | KDM4E (1.00) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL29963486 | 0.81 | KDM4E (1.00) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL6905408 | 0.80 | KDM4E (0.70) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL8876001 | 0.79 | KDM4E (0.76) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL27079801 | 0.78 | KDM4E (0.79) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL13609741 | 0.75 | KMT2A (0.64) | KDM4EHTR1AHTR2AKMT2AGAA | |
| SCHEMBL22475349 | 0.75 | KDM4E (0.64) | KDM4EHTR1AHTR2AKMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767916-B2 | 1-(4-METHYL-7-(3-METHYLBUT-2-ENYLOXY)COUMARIN-8-YL)-3-(PYRIDIN E-3-YL)- PROPEN-1-ONE FOR EXAMPLE; ANTIPROLIFERATIVE AGENT; TUMOR, CANCER TREATMENT | INDENA S.P.A. (IT) | 2004-07-27 | — | — | US | disclosed |
| EP-1212311-B1 | CHALCONE COUMARINS | INDENA SPA (IT) | 2003-03-26 | — | — | EP | disclosed |
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | INDENA S.P.A. (IT) | 2002-10-31 | — | — | US | disclosed |
| EP-1212311-A1 | CHALCONE COUMARINS | INDENA S.p.A. (IT) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001017984-A1 | CHALCONE COUMARINS | INDENA S.P.A. (IT) | 2001-03-15 | — | — | WO | disclosed |
| EP-0108036-A1 | Benzopyranones | CIBA-GEIGY AG (CH) | 1984-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161036-A1 | 1-(4-methyl-7-(3-methylbut-2-enyloxy)coumarin-8-yl)-3-(pyridin e-3-yl)- propen-1-one for example; antiproliferative agent; tumor, cancer treatment | NFKBIA, MKI67, HPD | KDM4E 201/4885HTR1A 3018/4885HTR2A 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.